Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. This phase IV, single-arm, open-label clinical trial evaluated the efficacy and safety of Canvert-M in males and females aged 18 to 55 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), for the treatment of migraine attacks.
The primary objective was to assess the reduction in headache intensity using a 4-point scale (0=no headache, 1=mild headache, 2=moderate headache, 3=severe headache).
Secondary objectives included evaluating additional efficacy and safety outcomes of Canvert-M in managing migraine attacks.
Males and females with age of 18 to 55 years
Age of migraine onset ˂ 50 years
Having a diagnosis of migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year
Having a history of 2-8 attacks per month
Having a diagnosis of other primary (cluster and tension) and secondary headache disorders
Having a history of chronic migraine headache
History of resistant or refractory migraine headaches based on European Headache Federation consensus
Receiving any abortive medication for the treatment of migraine within 48 hours before using Canvert-M